Skip to content

Development of shatpushpaa arka and its clinical evaluation in kashtaartava (dysmenorrhea)

Pharmaceutical standardization of shatpushpaa arka and its clinical evaluation in kashtaartava (dysmenorrhea) - NILL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076416
Enrollment
30
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Sponsors

Dr Denisha Chikhaliya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who are willing to participate in this study and gives informed written consent before trial. 2. Female in the age group of 18- 25 years. 3. Patients having regular menstrual cycle (21 to 35 days). 4. All the patients who are nulli or multipara women presenting with symptoms of Kashtaartava. 5. Patients who not take any kind of medication duration of trial.

Exclusion criteria

Exclusion criteria: 1.Female below the age of 18 years and above the 25 years age. 2.Patients having any pelvic pathology, Congenital anomalies, Acute infection, acyclic and excessive bleeding for more than 7 days, irregular menstrual cycle, Endometriosis, adenomyosis, uterine fibroid, endometrial polyp and other conditions resulting in dysmenorrhea. 3.Women suffering from systemic disease with organic lesion (benign or malignant growth of reproductive tract) any degree of prolapsed and hypoplastic uterus, polycystic ovarian disease (PCOD), any congenital abnormality of genital track.

Design outcomes

Primary

MeasureTime frame
Changes of VAS of pain during menstrual period. VAS score of 1-10 mm will be used for assessment.Timepoint: 1. Baseline - before starting the medicaments (first assessment) 2. After completion of 2 cycle of menstruation

Secondary

MeasureTime frame
Changes in symptoms & signs of dysmenorrhea. Present or absent of constipation, headache, nausea, fatigue, anorexia, vertigo & nervousness before & after the administration of medicaments.Timepoint: 1. Baseline - before starting the medicaments (first assessment) 2. After completion of 2 cycle of menstruation

Countries

India

Contacts

Public ContactDr Denisha Chikhaliya

J.S. Ayurveda Mahavidyalaya

drupendrazala16@gmail.com8401824975

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026